X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA BIOCON LTD AJANTA PHARMA/
BIOCON LTD
 
P/E (TTM) x 24.9 82.9 30.1% View Chart
P/BV x 10.3 7.8 131.8% View Chart
Dividend Yield % 0.6 0.2 367.2%  

Financials

 AJANTA PHARMA   BIOCON LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
BIOCON LTD
Mar-17
AJANTA PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,162 148.0%   
Low Rs1,103483 228.6%   
Sales per share (Unadj.) Rs194.6194.6 100.0%  
Earnings per share (Unadj.) Rs45.234.4 131.4%  
Cash flow per share (Unadj.) Rs50.348.3 104.2%  
Dividends per share (Unadj.) Rs8.001.00 800.0%  
Dividend yield (eoy) %0.60.1 466.0%  
Book value per share (Unadj.) Rs132.0241.9 54.6%  
Shares outstanding (eoy) m88.77200.00 44.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.34.2 171.6%   
Avg P/E ratio x31.223.9 130.6%  
P/CF ratio (eoy) x28.117.0 164.7%  
Price / Book Value ratio x10.73.4 314.5%  
Dividend payout %17.72.9 608.7%   
Avg Mkt Cap Rs m125,299164,440 76.2%   
No. of employees `000NA9.2 0.0%   
Total wages/salary Rs m2,5707,470 34.4%   
Avg. sales/employee Rs ThNM4,213.9-  
Avg. wages/employee Rs ThNM809.0-  
Avg. net profit/employee Rs ThNM745.2-  
INCOME DATA
Net Sales Rs m17,27538,911 44.4%  
Other income Rs m1661,571 10.6%   
Total revenues Rs m17,44240,482 43.1%   
Gross profit Rs m5,8079,795 59.3%  
Depreciation Rs m4512,772 16.3%   
Interest Rs m49260 18.8%   
Profit before tax Rs m5,4748,334 65.7%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4601,616 90.3%   
Profit after tax Rs m4,0146,881 58.3%  
Gross profit margin %33.625.2 133.5%  
Effective tax rate %26.719.4 137.5%   
Net profit margin %23.217.7 131.4%  
BALANCE SHEET DATA
Current assets Rs m7,63940,477 18.9%   
Current liabilities Rs m2,71516,783 16.2%   
Net working cap to sales %28.560.9 46.8%  
Current ratio x2.82.4 116.7%  
Inventory Days Days4360 72.5%  
Debtors Days Days7983 95.0%  
Net fixed assets Rs m6,91445,073 15.3%   
Share capital Rs m1771,000 17.7%   
"Free" reserves Rs m11,44247,377 24.2%   
Net worth Rs m11,72148,377 24.2%   
Long term debt Rs m14921,082 0.7%   
Total assets Rs m14,81493,942 15.8%  
Interest coverage x112.933.1 341.7%   
Debt to equity ratio x00.4 2.9%  
Sales to assets ratio x1.20.4 281.5%   
Return on assets %27.47.6 360.8%  
Return on equity %34.214.2 240.8%  
Return on capital %46.512.6 369.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42212,988 80.2%   
Fx outflow Rs m1,6787,899 21.2%   
Net fx Rs m8,7445,089 171.8%   
CASH FLOW
From Operations Rs m3,2646,400 51.0%  
From Investments Rs m-2,093-4,985 42.0%  
From Financial Activity Rs m-1,186-1,775 66.8%  
Net Cashflow Rs m-15-473 3.1%  

Share Holding

Indian Promoters % 73.8 40.4 182.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 1.6 8.4 18.5%  
FIIs % 7.6 10.7 71.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 19.9 85.4%  
Shareholders   20,968 109,995 19.1%  
Pledged promoter(s) holding % 4.4 0.0 10,975.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  STRIDES SHASUN LTD  FULFORD INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS